Pages that link to "Q40706569"
Jump to navigation
Jump to search
The following pages link to Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects (Q40706569):
Displaying 50 items.
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT (Q24685958) (← links)
- Nonmyeloablative allogeneic hematopoietic cell transplantation (Q26748780) (← links)
- Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published Literature (Q26749454) (← links)
- Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation (Q26852474) (← links)
- Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy (Q27010653) (← links)
- Advances in the autologous and allogeneic transplantation strategies for multiple myeloma (Q27014801) (← links)
- Current and emerging strategies for the prevention of graft-versus-host disease (Q27016541) (← links)
- Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments (Q28067102) (← links)
- Hematopoietic cell transplantation beyond first remission (Q28200716) (← links)
- Transplantation in Waldenstrom's macroglobulinemia—the French experience (Q28201747) (← links)
- IL-7 in allogeneic transplant: clinical promise and potential pitfalls (Q28259144) (← links)
- Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model (Q30525173) (← links)
- Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial (Q30543777) (← links)
- Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies (Q33342453) (← links)
- Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita (Q33346928) (← links)
- Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution. (Q33360252) (← links)
- Human platelet antigen systems in allogeneic peripheral blood progenitor cell transplantation: effect of human platelet antigen mismatch on platelet engraftment and graft-versus-host disease (Q33360549) (← links)
- Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin (Q33363625) (← links)
- Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning (Q33386036) (← links)
- Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs (Q33396929) (← links)
- Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome (Q33560410) (← links)
- Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation (Q33574209) (← links)
- Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial (Q33653406) (← links)
- The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation (Q33654676) (← links)
- Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation (Q33677489) (← links)
- Aspergillus infections in transplant recipients (Q33719294) (← links)
- Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience (Q33763908) (← links)
- Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms (Q33771667) (← links)
- Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model (Q33811417) (← links)
- Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome (Q33813439) (← links)
- Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation (Q33838584) (← links)
- Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan (Q33841438) (← links)
- Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia (Q33886217) (← links)
- Conditioning regimens for hematopoietic cell transplantation: one size does not fit all (Q33917170) (← links)
- Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. (Q33930149) (← links)
- Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma (Q33933025) (← links)
- High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. (Q33950015) (← links)
- Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. (Q33978945) (← links)
- Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation (Q34111627) (← links)
- Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation (Q34124707) (← links)
- Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. (Q34140624) (← links)
- Allogeneic hematopoietic cell transplantation: the state of the art (Q34145155) (← links)
- Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning (Q34197491) (← links)
- A preclinical canine model for composite tissue transplantation (Q34286899) (← links)
- Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation (Q34292970) (← links)
- Oral complications of cancer and cancer therapy: from cancer treatment to survivorship (Q34299445) (← links)
- Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning (Q34325183) (← links)
- Allogeneic hematopoietic cell transplantation for multiple myeloma (Q34326524) (← links)
- Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression (Q34340643) (← links)
- Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis (Q34360641) (← links)